Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 147 for:    visilizumab

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03291249
Recruitment Status : Withdrawn (Due to MOH request.)
First Posted : September 25, 2017
Last Update Posted : September 12, 2019
Sponsor:
Information provided by (Responsible Party):
Tiziana Life Sciences, PLC

Brief Summary:

This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for 30 consecutive days. Subjects will record adverse events and daily administration of study medication in a subject diary. This will serve as a measure of compliance and record of safety and tolerability. Subjects will be followed up for 30 days following completion of treatment.

Study visits performed on Days 14, 30 and 60 of the study, will monitor metabolic parameters (body mass index [BMI] and waist circumference), serum lipid profiles, immunological markers (c-reactive protein [CRP] and an array of cytokines), hepatic enzymes and functions (13C-methacetin breath test [MBT]) and liver steatosis/fibrosis, which will be compared to baseline levels (Day 1).

The safety and tolerability of the treatment regimen will be determined by monitoring vital signs, laboratory values, adverse events and physical findings throughout the study. In addition, its efficacy will be established upon either reduced Day 30 serum alanine aminotransferase (ALT) levels, reduced hemoglobin A1c (HbA1c) or improved homeostasis model assessment (HOMA) or HOMA of insulin resistance (HOMA-IR) scores as compared to baseline (Day 1). In addition, to assess the efficacy of the tested Foralumab Solution regimen in improving overall subject status, a battery of exploratory metabolic, immunologic and hepatic markers will be evaluated on Days 30 and 60.


Condition or disease Intervention/treatment Phase
NASH - Nonalcoholic Steatohepatitis NAFLD T2DM (Type 2 Diabetes Mellitus) Drug: Foralumab Other: placebo Drug: Omeprazole 20mg Phase 2

Detailed Description:

A randomized, placebo-controlled, double-blind, phase IIa study for assessment of the safety of Foralumab, an oral anti-CD3 antibody, in patients with nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM).

This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for 30 consecutive days. Subjects will record adverse events and daily administration of study medication in a subject diary. This will serve as a measure of compliance and record of safety and tolerability. Subjects will be followed up for 30 days following completion of treatment.

Study visits performed on Days 14, 30 and 60 of the study, will monitor metabolic parameters (body mass index [BMI] and waist circumference), serum lipid profiles, immunological markers (c-reactive protein [CRP] and an array of cytokines), hepatic enzymes and functions (13C-methacetin breath test [MBT]) and liver steatosis/fibrosis, which will be compared to baseline levels (Day 1).

The safety and tolerability of the treatment regimen will be determined by monitoring vital signs, laboratory values, adverse events and physical findings throughout the study. In addition, its efficacy will be established upon either reduced Day 30 serum alanine aminotransferase (ALT) levels, reduced hemoglobin A1c (HbA1c) or improved homeostasis model assessment (HOMA) or HOMA of insulin resistance (HOMA-IR) scores as compared to baseline (Day 1). In addition, to assess the efficacy of the tested Foralumab Solution regimen in improving overall subject status, a battery of exploratory metabolic, immunologic and hepatic markers will be evaluated on Days 30 and 60.

Primary: To assess the safety and tolerability of the tested Foralumab Solution regimen in subjects with both T2DM and NASH/NAFLD Secondary: To assess the efficacy of the tested Foralumab Solution regimen in improving serum ALT levels, HbA1c, HOMA or HOMA-IR scores in subjects with both T2DM and NASH/NAFLD.

Exploratory: To assess the efficacy of the tested Foralumab Solution regimen in improving overall subject status, as measured by a battery of metabolic, immunologic and hepatic markers.

48 adult subjects (≥18 years) with T2DM and who meet the inclusion criteria for NASH or NAFLD 2a Up to 25 Foralumab (TZLS-0401) is a fully human IgG1 monoclonal antibody directed against the CD3-epsilon (or CD3ε) antigen expressed on the surface of a type of white blood cell called T-cells, or T-lymphocytes. The Fc region of the antibody is mutated to reduce the cytokine release syndrome associated with parenteral administration of anti CD3. When administered orally, Foralumab is not absorbed and induces a signal at the level of the gut immune system to promote regulatory T cells systemically.

A once-daily oral dose of Foralumab solution (0.5, 2.5 or 5.0 mg) or placebo solution will be taken in the morning on an empty stomach for 30 consecutive days.

Group A will receive placebo solution for 30 days (n=12) Group B will receive 0.5 mg Foralumab Solution daily for 30 days (n=12) Group C will receive 2.5 mg Foralumab Solution daily for 30 days (n=12) Group D will receive 5.0 mg Foralumab Solution daily for 30 days (n=12)

A single 20 mg omeprazole pill will be concomitantly administered daily.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled ,Double-blind, Phase IIa Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Estimated Study Start Date : December 1, 2017
Estimated Primary Completion Date : December 1, 2018
Estimated Study Completion Date : June 1, 2019


Arm Intervention/treatment
Placebo Comparator: Group A
Group A will receive placebo solution for 30 consecutive days
Other: placebo
Placebo oral solution

Drug: Omeprazole 20mg
Omeprazole is a proton pump inhibitor used to neutralize stomach PH

Experimental: Group B
Group B will receive 0.5 mg Foralumab Solution daily for 30 consecutive days
Drug: Foralumab
Anti CD3 mAb
Other Name: Anti CD3

Drug: Omeprazole 20mg
Omeprazole is a proton pump inhibitor used to neutralize stomach PH

Experimental: Group C
Group B will receive 2.5 mg Foralumab Solution daily for 30 consecutive days
Drug: Foralumab
Anti CD3 mAb
Other Name: Anti CD3

Drug: Omeprazole 20mg
Omeprazole is a proton pump inhibitor used to neutralize stomach PH

Experimental: Group D
Group B will receive 5.0 mg Foralumab Solution daily for 30 consecutive days
Drug: Foralumab
Anti CD3 mAb
Other Name: Anti CD3

Drug: Omeprazole 20mg
Omeprazole is a proton pump inhibitor used to neutralize stomach PH




Primary Outcome Measures :
  1. severity and duration for all adverse events [ Time Frame: 30 days after last dose ]
    Incidence, severity, and duration for all adverse events (AEs), and abnormal laboratory and physical findings up until 30 days after last dose

  2. Abnormal laboratory findings [ Time Frame: 30 days after last dose ]
    Incidence, severity, and duration for all adverse events (AEs), and abnormal laboratory and physical findings up until 30 days after last dose

  3. Abnormal physical findings [ Time Frame: 30 days after last dose ]
    Incidence, severity, and duration for all adverse events (AEs), and abnormal laboratory and physical findings up until 30 days after last dose


Secondary Outcome Measures :
  1. Change ALT levels [ Time Frame: Day 30 versus Day 1 serum ALT levels ]
    Day 30 versus Day 1 serum ALT levels

  2. Change in HbA1c levels [ Time Frame: Day 30 versus Day 1 ]
    HbA1c levels

  3. change in HOMA/HOMA-IR scores [ Time Frame: Day 30 versus Day 1 ]
    Day 30 versus Day 1 change in HOMA/HOMA-IR scores. Insulin and fasting plasma glucose will be measured to calculate HOMA/HOMA-IR


Other Outcome Measures:
  1. Body mass index (BMI) [ Time Frame: Day 1 versus day 30 and 60 ]
    Measurment of BMI (kg/m^2) Serum lipid profile: total cholesterol, triglycerides, low density lipoprotein (LDL) and high density lipoprotein (HDL) fractions.

  2. Change in Immunological markers [ Time Frame: Day 1 versus day 30 and 60 ]
    C-reactive protein (CRP) b. T cell-associated cytokine levels (IL2, 4, 5, 6, 8,10,12, 13, IFN, TNF, TGF c. Regulatory T cell (Tregs) levels (cells positive for: CD4, CD25, CD8, CD56, CD3, CD62, CD127, NKT, FoxP3, LAP)

  3. Cytokine levels [ Time Frame: Day 1 versus day 30 and 60 ]
    Measurement of Cytokine levels Mean serum concentrations of, cytokeratin (CK)-18 fragments, C-peptide, glucagon-like peptide-1 (GLP-1), adiponectin c. 13C-Methacetin breath test (MBT) Hepatic steatosis and fibrosis

  4. waist circumference [ Time Frame: Day 1 versus day 30 and 60 ]
    measurement of waist circumference (cm)

  5. Serum lipid profile [ Time Frame: Day 1 versus day 30 and 60 ]
    Serum lipid concentration will be measured

  6. Regulatory T cell [ Time Frame: Day 1 versus day 30 and 60 ]
    Measurement of Regulatory T cell

  7. Liver enzymes [ Time Frame: Day 1 versus day 30 and 60 ]
    Measurement of Liver enzymes

  8. Mean serum concentrations of cytokeratin (CK)-18 fragments [ Time Frame: Day 1 versus day 30 and 60 ]
    Measurement of (CK)-18 fragments concentration

  9. Mean serum concentrations of C-peptide [ Time Frame: Day 1 versus day 30 and 60 ]
    Measurement of C-peptide concentration

  10. Mean serum concentrations of glucagon-like peptide-1 (GLP-1) [ Time Frame: Day 1 versus day 30 and 60 ]
    Measurement of glucagon-like peptide-1 (GLP-1) concentration

  11. Mean serum concentrations of adiponectin [ Time Frame: Day 1 versus day 30 and 60 ]
    Measurement of adiponectin concentration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Provision of written informed consent
  • Diagnosis of T2DM
  • HbA1c < 9.0 while on standard of care
  • Historical histology-based confirmation of NASH within 12 months prior to screening OR

Diagnosis of NAFLD based on all the following:

  • Presentation of at least one other parameter of the metabolic syndrome from the following list of three:

    (i) hypertension [≥130/85 mmHg or regularly taking an antihypertensive], (ii) dyslipidemia with high serum triglycerides [≥150 mg/dL or regularly taking medicines to lower high triglyceride levels] or low serum HDL [<50 mg/dL for women and <40 mg/dL for men], (iii) obesity (BMI > 30 kg/m2) or central obesity [waistline measurement ≥ 89 cm for women and ≥ 102 cm for men])

  • ALT > 40 IU
  • Fat fraction >10% in MRI performed during screening or up to 3 months prior to screening.
  • Agree to the use of effective contraceptive measures, as defined in the protocol, if either male or female with child-bearing potential.

Exclusion criteria:

  • Subject with cirrhosis per biopsy (fibrosis staging score >= 4) or Fibroscan® >14 kPa within 12 months of screening.
  • Presence of vascular liver disease
  • Any history or evidence of decompensated liver disease such as recurrent variceal bleeding, refractory ascites or hepatic encephalopathy
  • Known history of chronic alcoholic liver disease, chronic hepatitis B or C infection, drug-induced liver injury (DILI), hemochromatosis, Wilson's disease, 1-antitrypsin deficiency, primary biliary cirrhosis or secondary sclerosing cholangitis, autoimmune hepatitis
  • Known HIV antibody-positive
  • History of liver transplantation
  • BMI <25kg/m2
  • Clinically significant alcohol use
  • Score of ≥ 2 on the CAGE questionnaire, OR
  • Any subject with current significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening, as determined by medical history (medical chart review and/or interview). Significant alcohol consumption is defined as: females: >20 g/day; males: >30 g/day, with a standard drink in the US averaging 14 g alcohol.
  • Type 1 diabetes
  • Bariatric surgery within the last 5 years
  • Weight loss or gain of ≥5 kg in the past 6 months or >10% change in bodyweight in the past 12 months
  • Inadequate vascular access on physical examination
  • Lactating/breastfeeding/pregnant at screening
  • On an elemental diet or parenteral nutrition
  • Concurrent conditions
  • Inflammatory bowel disease
  • Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24 weeks of screening
  • Ongoing infectious disease, excluding recurrent urinary tract infection treated with long-term antibiotic prophylaxis
  • Any type of immune-mediated and/or malignant disease
  • Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the participating subject or on the interpretation of the study data
  • Concurrent medications including:
  • Amiodarone taken within 30 days of Day 1 (MBT contraindication)
  • Beta-blockers: must be on a stable dose for at least 30 days prior to Day 1 (MBT contraindication)
  • Statins: must be on a stable dose for at least 30 days prior to Day 1 (MBT contraindication)
  • The following medications taken every day for more than 1 week over the last three months: S-adenosyl methionine (SAM-e), betaine, milk thistle and probiotic supplements (other than yoghurt) with the exception of vitamin E or gemfibrozil, which are allowed

    ** If >= 400 IU vitamin E on a regular basis or gemfibrozil, at any dose, are used, the dose must be stable for more than 3 months;

  • immunomodulatory agents including In the last 4 weeks

    • oral or parenteral antibiotics
    • daily treatment with non-steroidal anti-inflammatory drugs (e.g., aspirin (>100 mg/day), ibuprofen, naproxen, imeloxicam, celecoxib)

In the last 3 months

  • systemic steroids
  • daily treatment with non-steroidal anti-inflammatory drugs (e.g., aspirin (>100mg/day), ibuprofen, naproxen, meloxicam, celecoxib) over 4 or more weeks in the last 3 months
  • variable dose of antilipidemic agents (HMG Co-A reductase inhibitors - "statins"). Subjects on stable dose of statins are eligible if missed no more than one week of dosing over the last 3 months

In the last 12 months

o azathioprine, 6-mercaptopurine, methotrexate, cyclosporin, anti-TNF alpha therapies (infliximab, adalimumab, etanercept) or anti-integrin therapies

  • Any of the following laboratory abnormalities:
  • Neutrophil count ≤1.0 x 109/L
  • Platelets <100 x 109/L
  • Hemoglobin <10g/dL
  • Albumin <3.5g
  • International Normalized Ratio (INR) >1.5
  • Total bilirubin >1.5 x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
  • Either creatinine clearance ≤60mL/minute, calculated by Cockroft Gault, or creatinine >1.5x upper limit of reference range
  • Regular use of marijuana or marijuana-related products, or use of cocaine, or street drugs, as determined by medical history (medical chart review and/or interview).
  • Subjects with symptoms of significant mental illness, inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to provide informed consent.
  • Hypersensitivity to methacetin and/or its metabolites (i.e., paracetamol, acetaminophen)

Layout table for additonal information
Responsible Party: Tiziana Life Sciences, PLC
ClinicalTrials.gov Identifier: NCT03291249     History of Changes
Other Study ID Numbers: TZLS-0401-001
First Posted: September 25, 2017    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: August 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Visilizumab
Fatty Liver
Non-alcoholic Fatty Liver Disease
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Liver Diseases
Digestive System Diseases
Omeprazole
Antibodies
Muromonab-CD3
Immunologic Factors
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents